NCT02660034 is a Phase 1 clinical trial of Tislelizumab in Solid Tumors, sponsored by BeiGene.

Who is sponsoring NCT02660034?

NCT02660034 is sponsored by BeiGene.

What drugs are being tested in NCT02660034?

Interventions in NCT02660034: Tislelizumab, Pamiparib.

What condition does NCT02660034 study?

NCT02660034 studies Solid Tumors.

Is NCT02660034 still recruiting?

NCT02660034 is currently completed. Last updated 6 December 2021.

Are results published for NCT02660034?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-12-06 · How we verify

NCT02660034

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Completed Phase 1 Results posted Last updated 6 December 2021

What this trial tests

Phase 1 trial testing Tislelizumab in Solid Tumors in 229 participants. Completed in 9 September 2020.

Timeline

2 February 2016

Primary endpoint
9 September 2020

9 September 2020

Quick facts

Lead sponsor	BeiGene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	229
Start date	2 February 2016
Primary completion	9 September 2020
Estimated completion	9 September 2020
Sites	29 locations across France, New Zealand, United Kingdom, Australia, United States, Spain

Drugs / interventions tested

Tislelizumab (TISLELIZUMAB) — full drug profile →
Pamiparib — full drug profile →

Conditions studied

Solid Tumors — all drugs for Solid Tumors →

Sponsor

BeiGene — full company profile →

Who can join

18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Part A: Number Of Participants Experiencing Adverse Events (AEs) Primary · From Day 1 up to 4 years and 7 months

An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardl

Group	Value	95% CI
Part A: Dose Escalation Phase - Cohort 1	12
Part A: Dose Escalation Phase - Cohort 2	12
Part A: Dose Escalation Phase - Cohort 3	6
Part A: Dose Escalation Phase - Cohort 4	13
Part A: Dose Escalation Phase - Cohort 5	6

Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT) Primary · 21 days following the first dose of tislelizumab and pamiparib in Cycle 1

DLT was defined as an AE or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications, and occurs during the first 21 days following the first dose of tislelizumab and pamiparib in Cycle 1 and meets protocol-specified criteria. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.

Group	Value	95% CI
Part A: Dose Escalation Phase - Cohort 1	0
Part A: Dose Escalation Phase - Cohort 2	0
Part A: Dose Escalation Phase - Cohort 3	0
Part A: Dose Escalation Phase - Cohort 4	2
Part A: Dose Escalation Phase - Cohort 5	2

Part B: Objective Response Rate (ORR) Primary · Starting from Day 1 until disease progression (up to 4 years and 7 months)

ORR was defined as the percentage of participants with a best overall response of complete response (CR) and partial response (PR).

Group	Value	95% CI
Part B: Dose Expansion Phase - Arm 1a	7
Part B: Dose Expansion Phase - Arm 1b	3
Part B: Dose Expansion Phase - Arm 2	9
Part B: Dose Expansion Phase - Arm 3	4
Part B: Dose Expansion Phase - Arm 4	2
Part B: Dose Expansion Phase - Arm 5	2
Part B: Dose Expansion Phase - Arm 6	6
Part B: Dose Expansion Phase - Arm 7	0
Part B: Dose Expansion Phase - Arm 8	3

Part B: Progression-free Survival (PFS) Primary · Starting from Day 1 until disease progression (up to 4 years and 7 months)

PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.

Group	Value	95% CI
Part B: Dose Expansion Phase - Arm 1a	8.2	5.2 – 11.8
Part B: Dose Expansion Phase - Arm 1b	3.5	1.9 – 7.6
Part B: Dose Expansion Phase - Arm 2	8.4	3.9 – 19.0
Part B: Dose Expansion Phase - Arm 3	10.4	4.3 – 16.2
Part B: Dose Expansion Phase - Arm 4	2.0	1.7 – 2.3
Part B: Dose Expansion Phase - Arm 5	2.1	1.9 – 4.1
Part B: Dose Expansion Phase - Arm 6	3.5	1.9 – 7.5
Part B: Dose Expansion Phase - Arm 7	1.9	1.1 – 2.1
Part B: Dose Expansion Phase - Arm 8	2.2	1.2 – 24.4

Part B: Duration Of Response (DOR) Primary · Starting from Day 1 until disease progression (up to 4 years and 7 months)

DOR, defined as the time from the first determination of an objective response, was assessed by investigator per Response Evaluation Criteria in Solid Tumors v1.1 until the first documentation of progression or death, whichever occurred first. Results are reported only for arms with responders.

Group	Value	95% CI
Part B: Dose Expansion Phase - Arm 1a	11.2	6.2 – NA
Part B: Dose Expansion Phase - Arm 1b	6.2	3.8 – NA
Part B: Dose Expansion Phase - Arm 2	17.1	3.0 – NA
Part B: Dose Expansion Phase - Arm 3	NA	4.1 – NA
Part B: Dose Expansion Phase - Arm 4	6.2	4.3 – 8.1
Part B: Dose Expansion Phase - Arm 5	NA	NA – NA
Part B: Dose Expansion Phase - Arm 6	NA	5.7 – NA
Part B: Dose Expansion Phase - Arm 8	NA	22.4 – NA

Part B: Disease Control Rate (DCR) Primary · Starting from Day 1 until disease progression (up to 4 years and 7 months)

DCR was defined as the percentage of participants with a best overall response of CR, PR, and stable disease (SD).

Group	Value	95% CI
Part B: Dose Expansion Phase - Arm 1a	21
Part B: Dose Expansion Phase - Arm 1b	11
Part B: Dose Expansion Phase - Arm 2	14
Part B: Dose Expansion Phase - Arm 3	15
Part B: Dose Expansion Phase - Arm 4	7
Part B: Dose Expansion Phase - Arm 5	7
Part B: Dose Expansion Phase - Arm 6	12
Part B: Dose Expansion Phase - Arm 7	2
Part B: Dose Expansion Phase - Arm 8	4

Part B: Clinical Benefit Rate (CBR) Primary · Starting from Day 1 until disease progression (up to 4 years and 7 months)

CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.

Group	Value	95% CI
Part B: Dose Expansion Phase - Arm 1a	15
Part B: Dose Expansion Phase - Arm 1b	7
Part B: Dose Expansion Phase - Arm 2	11
Part B: Dose Expansion Phase - Arm 3	10
Part B: Dose Expansion Phase - Arm 4	4
Part B: Dose Expansion Phase - Arm 5	4
Part B: Dose Expansion Phase - Arm 6	8
Part B: Dose Expansion Phase - Arm 7	1
Part B: Dose Expansion Phase - Arm 8	3

Part B: Overall Survival (OS) Primary · From Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)

OS was defined as the time from the date of first dose of study drug to death due to any cause.

Group	Value	95% CI
Part B: Dose Expansion Phase - Arm 1a	20.9	13.5 – NA
Part B: Dose Expansion Phase - Arm 1b	18.7	6.1 – 27.0
Part B: Dose Expansion Phase - Arm 2	15.8	10.4 – NA
Part B: Dose Expansion Phase - Arm 3	21.2	10.5 – NA
Part B: Dose Expansion Phase - Arm 4	6.9	3.3 – 11.5
Part B: Dose Expansion Phase - Arm 5	7.4	3.3 – 13.4
Part B: Dose Expansion Phase - Arm 6	8.4	4.4 – 17.1
Part B: Dose Expansion Phase - Arm 7	4.1	2.9 – 5.0
Part B: Dose Expansion Phase - Arm 8	4.1	1.2 – 19.5

Part A: Minimum Observed Plasma Concentration (Ctrough) Of Tislelizumab Secondary · Cycle 4 Day 1 (0 hours and 4 hours) post dose

Cycle 4 Day 1 (Pre-dose)

Group	Value	95% CI
Part A: Dose Escalation Phase - Cohort 1	23530	± 48.02
Part A: Dose Escalation Phase - Cohort 2	26040	± 58.04
Part A: Dose Escalation Phase - Cohort 3	26160	± 23.69
Part A: Dose Escalation Phase - Cohort 4	30330	± 58.28
Part A: Dose Escalation Phase - Cohort 5	53700	± 81.62

Cycle 4 Day 1 (4 h)

Group	Value	95% CI
Part A: Dose Escalation Phase - Cohort 1	74260	± 20.70
Part A: Dose Escalation Phase - Cohort 2	66250	± 47.28
Part A: Dose Escalation Phase - Cohort 3	69020	± 16.47
Part A: Dose Escalation Phase - Cohort 4	104300	± 35.31
Part A: Dose Escalation Phase - Cohort 5	119600	± 33.83

Part A: Ctrough Of Pamiparib Secondary · Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)

Cycle 2 Day 1 (Pre-dose)

Group	Value	95% CI
Part A: Dose Escalation Phase - Cohort 1	772.9	± 164.6
Part A: Dose Escalation Phase - Cohort 2	1258	± 62.13
Part A: Dose Escalation Phase - Cohort 3	1209	± 42.18
Part A: Dose Escalation Phase - Cohort 4	1876	± 60.41
Part A: Dose Escalation Phase - Cohort 5	2754	± 48.69

Cycle 2 Day 1 (7 h)

Group	Value	95% CI
Part A: Dose Escalation Phase - Cohort 1	824.8	± 130.6
Part A: Dose Escalation Phase - Cohort 2	1469	± 38.14
Part A: Dose Escalation Phase - Cohort 3	1717	± 55.56
Part A: Dose Escalation Phase - Cohort 4	2070	± 47.36
Part A: Dose Escalation Phase - Cohort 5	2969	± 48.77

Part A: Maximum Observed Plasma Concentration At Steady State (Cmax,ss) Of Pamiparib Secondary · Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)

Group	Value	95% CI
Part A: Dose Escalation Phase - Cohort 1	1457
Part A: Dose Escalation Phase - Cohort 2	2497
Part A: Dose Escalation Phase - Cohort 3	2985
Part A: Dose Escalation Phase - Cohort 4	2586
Part A: Dose Escalation Phase - Cohort 5	3189

Part A: Time To Reach Maximum Plasma Concentration At Steady State (Tmax,ss) Of Pamiparib Secondary · Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)

Group	Value	95% CI
Part A: Dose Escalation Phase - Cohort 1	1.0	0.60 – 6.2
Part A: Dose Escalation Phase - Cohort 2	1.1	0.42 – 4.0
Part A: Dose Escalation Phase - Cohort 3	1.0	1.0 – 7.1
Part A: Dose Escalation Phase - Cohort 4	1.9	0.45 – 7.0
Part A: Dose Escalation Phase - Cohort 5	2.0	0.92 – 3.8

Adverse events — posted to ClinicalTrials.gov

Time frame: Day 1 through 4 years and 7 months. Reporting threshold: 3%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Part A: Dose Escalation Phase - Cohort 1

Serious: 5/12 (42%)

Deaths: 11/12

Part A: Dose Escalation Phase - Cohort 2

Serious: 5/12 (42%)

Deaths: 9/12

Part A: Dose Escalation Phase - Cohort 3

Serious: 3/6 (50%)

Deaths: 2/6

Part A: Dose Escalation Phase - Cohort 4

Serious: 6/13 (46%)

Deaths: 10/13

Part A: Dose Escalation Phase - Cohort 5

Serious: 5/6 (83%)

Deaths: 3/6

Part B: Dose Expansion Phase - Arm 1a

Serious: 6/23 (26%)

Deaths: 13/23

Part B: Dose Expansion Phase - Arm 1b

Serious: 16/23 (70%)

Deaths: 14/23

Part B: Dose Expansion Phase - Arm 2

Serious: 7/19 (37%)

Deaths: 10/19

Part B: Dose Expansion Phase - Arm 3

Serious: 8/20 (40%)

Deaths: 9/20

Part B: Dose Expansion Phase - Arm 4

Serious: 14/23 (61%)

Deaths: 21/23

Part B: Dose Expansion Phase - Arm 5

Serious: 10/20 (50%)

Deaths: 17/20

Part B: Dose Expansion Phase - Arm 6

Serious: 13/21 (62%)

Deaths: 15/21

Part B: Dose Expansion Phase - Arm 7

Serious: 8/21 (38%)

Deaths: 20/21

Part B: Dose Expansion Phase - Arm 8

Serious: 8/10 (80%)

Deaths: 8/10

Serious adverse events (114 terms)

Reaction	System	Part A: Dose Escalation Ph…	Part A: Dose Escalation Ph…	Part A: Dose Escalation Ph…	Part A: Dose Escalation Ph…	Part A: Dose Escalation Ph…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…
Small intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Immune-mediated hepatitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Spinal cord compression	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Ascites	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hepatitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Lower respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypophysitis	Endocrine disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant gastrointestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
General physical health deterioration	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Autoimmune hepatitis	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Malignant biliary obstruction	Hepatobiliary disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal sepsis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Other adverse events (96 terms — click to expand)

Reaction	System	Part A: Dose Escalation Ph…	Part A: Dose Escalation Ph…	Part A: Dose Escalation Ph…	Part A: Dose Escalation Ph…	Part A: Dose Escalation Ph…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…	Part B: Dose Expansion Pha…
Nausea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Fatigue	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Asthenia	General disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Hypothyroidism	Endocrine disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Bronchitis	Infections and infestations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Paraesthesia	Nervous system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pleural effusion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Blood bilirubin increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Weight decreased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Most-reported serious reactions: Small intestinal obstruction, Immune-mediated hepatitis, Spinal cord compression, Ascites, Vomiting, Pyrexia, Hepatitis, Pneumonia.

Data from ClinicalTrials.gov NCT02660034 adverse events section.

Sponsor's own description

This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Yi M, Zheng X, Niu M, Zhu S, et al · · 2022 · cited 1018× · PMID 35062949 · DOI 10.1186/s12943-021-01489-2
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S, Xia W, Yamaguchi H, Wei Y, et al · · 2017 · cited 793× · PMID 28167507 · DOI 10.1158/1078-0432.ccr-16-3215
Exploring treatment options in cancer: Tumor treatment strategies.
Liu B, Zhou H, Tan L, Siu KTH, et al · · 2024 · cited 536× · PMID 39013849 · DOI 10.1038/s41392-024-01856-7
DNA Damage and Repair Biomarkers of Immunotherapy Response.
Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. · · 2017 · cited 523× · PMID 28630051 · DOI 10.1158/2159-8290.cd-17-0226
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation.
O'Reilly EM, Lee JW, Zalupski M, Capanu M, et al · · 2020 · cited 274× · PMID 31976786 · DOI 10.1200/jco.19.02931
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M, Jia K, Wang L, Li W, et al · · 2021 · cited 236× · PMID 34729299 · DOI 10.1016/j.apsb.2021.01.003
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
Brown JS, Sundar R, Lopez J. · · 2018 · cited 178× · PMID 29123260 · DOI 10.1038/bjc.2017.376

Verify or expand the search:

Other trials of Tislelizumab

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting

Other recruiting trials for Solid Tumors

Currently open trials in the same condition.

NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting

Other BeiGene trials

Trials by the same sponsor.

NCT07169331 — A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglob · Phase 4 · recruiting
NCT07100938 — A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheum · Phase 2 · active not recruiting
NCT07005713 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB- · Phase 1 · active not recruiting
NCT06906809 — Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants · Phase 1 · completed
NCT06803680 — A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02660034 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BeiGene
Last refreshed: 6 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02660034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing